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Effects of Anti-Vascular Endothelial Growth Factor
Therapy for Cancer
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Sherry Bullens, BA,† Terry K. Morgan, MD, PHD,‡ Susan P. Bagby, MD,§ Ganesh Kolumam, PHD,†
Joe Kowalski, BS,† Jon A. Oyer, PHD, Stuart Bunting, PHD,† Jonathan R. Lindner, MD*
Portland, Oregon; and South San Francisco, California
Objectives This study sought to evaluate the contribution of microvascular functional rarefaction and changes in vascular
mechanical properties to the development of hypertension and secondary ventricular remodeling that occurs
with anti-vascular endothelial growth factor (VEGF) therapy.
Background Hypertension is a common side effect of VEGF inhibitors used in cancer medicine.
Methods Mice were treated for 5 weeks with an anti-murine VEGF-A monoclonal antibody, antibody plus ramipril, or sham
treatment. Microvascular blood flow (MBF) and blood volume (MBV) were quantified by contrast-enhanced ultra-
sound in skeletal muscle, left ventricle (LV), and kidney. Echocardiography and invasive hemodynamics were
used to assess ventricular function, dimensions and vascular mechanical properties.
Results Ambulatory blood pressure increased gradually over the first 3 weeks of anti-VEGF therapy. Compared with controls,
anti-VEGF–treated mice had similar aortic elastic modulus and histological appearance, but a marked increase in ar-
terial elastance, indicating increased afterload, and elevated plasma angiotensin II. Increased afterload in treated
mice led to concentric LV remodeling and reduced stroke volume without impaired LV contractility determined by LV
peak change in pressure over time (dp/dt) and the end-systolic dimension–pressure relation. Anti-VEGF therapy did
not alter MBF or MBV in skeletal muscle, myocardium, or kidney; but did produce cortical mesangial glomerulosclero-
sis. Ramipril therapy almost entirely prevented the adverse hemodynamic effects, increased afterload, and LV remod-
eling in anti-VEGF–treated mice.
Conclusions Neither reduced functional microvascular density nor major alterations in arterial mechanical properties are primary
causes of hypertension during anti-VEGF therapy. Inhibition of VEGF leads to an afterload mismatch state, increased
angiotensin II, and LV remodeling, which are all ameliorated by angiotensin-converting enzyme inhibition.
(J Am Coll Cardiol 2012;60:618–25) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.053Antagonists to vascular endothelial growth factor
(VEGF) such as humanized anti-human monoclonal
antibodies (mAbs) and small molecule inhibitors of
From the *Division of Cardiovascular Medicine, Oregon Health & Science Univer-
sity, Portland, Oregon; †Department of Tumor Biology and Angiogenesis, Genen-
tech Inc., South San Francisco, California; ‡Department of Pathology, Oregon
Health & Science University, Portland, Oregon; §Division of Nephrology and
Hypertension, Oregon Health & Science University, Portland, Oregon; and the
Vollum Institute, Oregon Health & Science University, Portland, Oregon. This
study was supported in part by a grant from Genentech Inc. Dr. Kaufmann is
supported by a research grant from the Lichtenstein Foundation. Dr. Morgan is
supported by the Office of Research on Women’s Health and the National Institute
of Child Health and Human Development, Oregon BIRCWH HD043488-08. Dr.
Lindner is supported by grants R01-HL-078610, R01-DK-063508, and RC1-HL-
100659 from the National Institutes of Health. All other authors have reported that
they have no relationships relevant to the contents of this paper to disclose.Manuscript received November 3, 2011; revised manuscript received February 2,
2012, accepted February 6, 2012.VEGF signaling are commonly used to treat cancers (1).
These drugs are associated with a high incidence of
hypertension and proteinuria (2–5). Several potential
mechanisms for hypertension have been proposed. Sys-
temic capillary rarefaction could contribute to hyperten-
sion by increasing vascular resistance, although there is
still ambiguity regarding whether capillary regression
See page 626
during VEGF inhibition is widespread throughout the sys-
temic circulation, or confined to specific vulnerable beds such
as the thyroid, the trachea, the intestinal villi, and the skin
(2,6–9). Hypertension from VEGF inhibitors could also be
secondary to increased vascular tone that occurs from a reduc-
tion in VEGF receptor–mediated nitric oxide (NO) produc-
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as endothelin-1 or angiotensin II (12). Renal effects of VEGF
inhibition such as thrombotic microangiopathy or renovascular
dysregulation may also contribute to hypertension (4,6,13,14).
The relative contribution of these events to hypertension is
uncertain.
In this study, we characterized the cardiovascular adap-
tations and multiorgan in vivo microvascular changes asso-
ciated with hypertension during anti-VEGF therapy in
mice. The microcirculation in the heart, kidney, and skeletal
muscle was assessed with contrast-enhanced ultrasound (CEU),
which provides quantitative information on not only micro-
vascular blood flow (MBF), but also microvascular blood
volume (MBV). This technique is able to evaluate func-
tional microvascular density, which is not necessarily
equivalent to anatomic microvascular density, in many
issues such as the heart and skeletal muscle, where only
fraction of capillaries are functionally patent at rest
15,16). Comprehensive evaluation of cardiac function
nd vascular mechanical properties were performed using
chocardiography and invasive manometry; whereas his-
ology was used to evaluate pathological changes in the
idney and the aorta.
ethods
tudy design. The study protocol was approved by the
nstitutional Animal Care and Use Committee at Oregon
ealth & Science University. Wild-type C57Bl/6 mice
n  83) and double-knockout mice (n  50) produced by
ene-targeted deletion of the low-density lipoprotein recep-
or and Apobec-1 mRNA editing peptide for apolipopro-
ein B were studied. The latter group was used to study
hether effects of VEGF inhibition were amplified in a
odel of pre-atherosclerotic hyperlipidemia. Baseline stud-
es were performed at 10 to 12 weeks of age and were
epeated after 5 weeks of either: 1) treatment biweekly with
phage-derived anti-murine VEGF-A mAb (G6-31, Ge-
entech, South San Francisco, California) (10 mg/kg intra-
eritoneally; 2) treatment with G6-31 and the angiotensin-
onverting enzyme inhibitor ramipril (5 mg/kg/day) added
o the drinking water; or 3) control injection with vehicle or
agweed pollen. For imaging protocols, mice were anesthe-
ized with 1.0% to 1.5% inhaled isoflurane.
chocardiography. Echocardiography (Vevo-770, Visual-
onics, Toronto, Ontario, Canada) was performed using a
igh-frequency (40 MHz) transducer. See the Online Ap-
endix for methods for evaluating left ventricular (LV)
imensions, systolic function, and stroke volume (SV).
emodynamic measurements. Invasive hemodynamic
easurements were performed only after completion of
herapy. A calibrated 1.4-F catheter-tip micromanometer
SPR-671, Millar Instruments, Houston, Texas) was in-
erted into the carotid artery and advanced retrograde into
he aorta. Systolic (SBP) and diastolic blood pressures were
ecorded, after which the catheter was advanced briefly intohe LV to measure peak positive
nd negative dp/dt. Aortic pulse
ressure (p) was combined with
ortic diameter measurements
D) to calculate aortic elastic
odulus by: (p  Dd)/D,
here Dd is aortic diastolic di-
meter. Arterial elastance was
alculated by: (0.9 SBP)/SV (17).
mbulatory blood pressure.
onscious ambulatory blood
ressure was measured using a
arotid artery catheter interfaced
ith a radiotelemetry pressure
ransducer (PA-C10, Data Sci-
nces International, St. Paul,
innesota). After allowing sev-
ral days for recovery, pressure
easurements were recorded at
aseline and twice weekly for 5
eeks after starting therapy with
6-31 (n  10) or control (rag-
eed pollen) injections (n  9).
icrovascular perfusion and
lood volume. Lipid-shelled
ecafluorobutane microbubbles were prepared (18). Perfu-
ion imaging of the myocardium, proximal hindlimb adduc-
or skeletal muscle, and kidney was performed using a
inear-array transducer (Sequoia 512, Siemens Medical
ystems, Malvern, Pennsylvania). The nonlinear fundamen-
al (7 MHz) signal component from the contrast agent was
etected using multipulse phase inversion and amplitude
odulation at a mechanical index of 0.2. Blood pool signal
ILV) was measured from a region of interest placed in the
LV cavity at end-diastole during a microbubble infusion rate
of 5  105 min1. Microbubble infusion rates were in-
creased to 5 106 min1 for myocardial and renal perfusion
maging, and 1  107 min1 for skeletal muscle perfusion.
Time-intensity data were acquired after a high-power (me-
chanical index: 1.1) 5-frame sequence and were fit to the
function: y  A(1  et), where y is intensity at time t, A is
he plateau intensity, and the rate constant – is the
microvascular flux rate (15,19). MBV was quantified by
(A)/(1.06  ILV  F  0.9), where 1.06 is tissue density
(g/cm3), F is the scaling factor for the different infusion rate
for ILV, which was reduced to avoid dynamic range satura-
tion, and 0.9 is a coefficient to correct for murine sternal
attenuation determined a priori. MBF was quantified by the
product of MBV and . In skeletal muscle, MBV in the
capillary compartment alone was measured by eliminating
signal from vessels with a velocity of2 mm/s (15). Skeletal
muscle MBF during exercise was measured after 2 min of
electrostimulated (5 mA) contraction of the adductor mus-
cles at 2 Hz. Renal vascular resistance was calculated by the
Abbreviations
and Acronyms
CEU  contrast-enhanced
ultrasound
LV  left
ventricle/ventricular
mAb  monoclonal
antibody
MBF  microvascular
blood flow
MBV  microvascular
blood velocity
MHC  myosin heavy chain
PAS  periodic acid–Schiff
rt-PCR  real-time
polymerase chain reaction
SBP  systolic blood
pressure
SV  stroke volume
VcF  velocity of
circumferential shortening
VEGF  vascular
endothelial growth factormean arterial pressure divided by the renal MBF.
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-myosin heavy chain mRNA. The mRNA for -myosin
eavy chain (MHC), atrial natriuretic peptide (ANP), and B-type
atriuretic peptide (BNP) was measured by real-time polymerase
hain reaction (rt-PCR) (Online Appendix).
ndothelial nitric oxide synthase phosphorylation. Phospho-
ylation of endothelial nitric oxide synthase (eNOS), which
ccurs downstream from VEGF receptor activation, was
valuated by enzyme-linked immunosorbent assay from
ardiac muscle samples (Online Appendix).
istology. For renal histology, periodic acid–Schiff (PAS)
taining of fixed paraffin-embedded coronal sections was
erformed. Sections were evaluated in triplicate blinded to
reatment. Glomerular and tubulointerstitial injury were
cored as 0  absent, 1  mild focal, 2  moderate
multifocal, or 3  severe diffuse cortical involvement. Renal
mmunohistology was performed using hamster anti-mouse
D31 (MAB1398Z, Chemicon/Millipore, Billerica, Mas-
achusetts) primary and Cy3-labeled secondary mAbs. Fi-
rin staining was performed with fluorescein isothiocyanate–
abeled anti-fibrinogen/fibrin primary mAb (AXL234F, Ac-
urate Chemical, Westbury, New York). Skeletal muscle mi-
rovascular density was assessed by immunohistochemistry
ith a Cy3-labeled smooth muscle -actin mAb (1A4, Sigma,
t. Louis, Missouri) and was expressed by the total microvessel
rea per muscle section area. Myocardial collagen content was
uantified by the percent area positive for picrosirius red
taining under polarized light. Myocyte cross-sectional area
as measured from 15 to 25 myocytes from 5 separate
ections stained with hematoxylin & eosin. Verhoeff elastin
taining of the aorta was performed to evaluate the number and
ean thickness of elastic lamina and thickness of the tunica
edia averaged from 4 separate radial locations. Elastin frag-
entation was scored blinded to treatment as 0  none, 1 
minimal, 2  mild, 3  moderate, or 4  severe.
Plasma and urine biomarkers. Plasma angiotensin II con-
centrations were determined using an enzyme immunoassay
(SPI-BIO, Montigny le Bretonneux, France) with an Ell-
man’s chromagenic reagent that has a minimum detectable
Echocardiography DataTable 1 Echocardiography Data
Control (n  18)
Week 0 Week 5
LVIDd, mm 3.4 0.2 3.3 0.2
LVIDs, mm 2.3 0.2 2.4 0.3
WTd, mm 0.66 0.09 0.68 0.09 0
LV mass, mg 66 13 66 12
Thickening fraction 0.56 0.14 0.53 0.15 0
SV, l 50 16 40 10
VcF, mm/s 0.66 0.15 0.60 0.17 0
S’, mm/s 15.8 4.6 12.9 4.7* 1
E’, mm/s 12.3 4.2 9.7 5.3* 1
Values are mean  SD. *p  0.05 versus week 0 data; †p  0.05 versus week 0 data and versus
6-31ramipril with respect to change in value from week 0 to week 5.
E’  peak early diastolic endocardial velocity; LVID  left ventricular internal dimension; S’  peak sys
WTd  diastolic wall thickness.concentration of 1 pg/ml. Urinary albumin concentration was
quantified by a competitive enzyme-linked immunosorbent
assay (Albuwell-M, Exocell, Philadelphia, Pennsylvania).
Statistical methods. Unless otherwise specified, data are
presented as mean SD. Effects of treatment were assessed
with a paired t test for normally distributed variables. Group
comparisons were made with 1-way analysis of variance
with t tests for independent samples and Bonferroni correc-
ion. Scored histopathology data were evaluated using either
Kruskal-Wallis test or a Mann-Whitney test for inter-
roup comparisons. rt-PCR data were compared with a
ann-Whitney test. A p value of 0.05 was considered
ignificant. Since within each treatment group there were no
ignificant differences between wild-type and double-
nockout mice for any baseline or post-treatment hemody-
amic or echocardiographic parameters, data were com-
ined for the 2 groups.
esults
ardiovascular and hemodynamic effects of VEGF inhibition.
n sham-treated mice, there were no significant changes in
V dimensions, mass, or echocardiographic measures of
ystolic function over the 5-week treatment period (Table 1).
nhibition of VEGF with G6-31 for 5 weeks produced a
ignificant increase in LV wall thickness and mass, and a
ecrease in end-diastolic diameter consistent with concen-
ric hypertrophy. The presence of hypertrophy in G6-31
ompared with control mice was further supported by larger
yocyte cross-sectional area (122  15 m2 vs. 100 
13 m2, p  0.04) and higher ventricular expression of
-MHC, ANP, and BNP mRNA on rtPCR (Online Fig. A),
although myocardial collagen area on histology was similar
(2.7 1.1% vs. 2.8 1.3%, p 0.91; n 6 each; examples
hown in Online Fig. B). In G6-31–treated animals, there
as also a reduction in thickening fraction, SV, and velocity
f circumferential shortening (VcF) (Table 1). All of the
hanges in ventricular size and function in G6-31–treated
ice were completely attenuated by ramipril co-administration.
G6-31 (n  18) G6-31Ramipril (n  14)
0 Week 5 Week 0 Week 5
0.2 3.1 0.3* 3.6 0.3 3.5 0.4
0.3 2.4 0.3 2.5 0.3 2.6 0.4
0.09 0.79 0.06†‡ 0.66 0.12 0.68 0.08
12 73 8* 67 13 68 13
0.19 0.38 0.12* 0.54 0.21 0.42 0.11
10 31 7* 45 12 42 24
0.13 0.48 0.18* 0.54 0.12 0.49 0.17
3.0 12.3 4.7* 15.6 2.7 12.2 4.9*
5.6 9.7 2.7* 13.6 5.7 10.3 3.3*
control and G6-31ramipril (corrected for multiple comparisons); ‡p  0.05 versus control andWeek
3.4
2.3
.65
66
.63
45
.69
5.2
3.6
week 5tolic endocardial velocity; SV  stroke volume; VcF  velocity of circumferential fiber shortening;
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age-dependent decrease in S= and E=, the degree of which
was not significantly different between treatment groups.
On invasive hemodynamic evaluation, G6-31–treated
mice had higher SBP, diastolic blood pressure, and peak
positive and negative LV dp/dt than either the control or
G6-31ramipril cohort (Table 2). The degree of hyperten-
Hemodynamics and Aortic Mechanical PropertiesTable 2 Hemodynamics and Aortic Mechanical Properties
Control
(n  12)
G6-31
(n  10)
G6-31Ramipril
(n  9)
SBP, mm Hg 99 7 108 9* 98 6
DBP, mm Hg 65 8 76 8* 66 8
LVdp/dt, mm Hg/s 9,070 1,995 10,508 1,407 8,042 1,660
LVdp/dt, mm Hg/s 7,320 2,245 8,624 2,369 7,469 2,283
Elastic modulus, KPa 28.0 8.3 31.3 8.5 29.3 10.1
EA, mm Hg/l 3.4 1.0 4.4 1.3† 3.7 1.7
Values are mean SD. *p 0.05 versus control and G6-31ramipril; †p 0.05 versus control only.
Abbreviations as in Table 1.
Figure 1 Ascending Thoracic Aorta Histology
Mean (SEM) (A) thickness of the tunica media, (B) number of elastic lamina, an
apy. (D) Elastic lamina fragmentation scores, expressed as a proportion for each
ascending aorta illustrating normal (top) and mild fragmentation (bottom, arrow)
in each group.sion caused by G6-31 was even more prominent on con-
scious ambulatory recordings with a 17  11%, 25  11%,
nd 38  11% increase in SBP for weeks 1, 2, and 3 of
herapy, respectively (analysis of variance p  0.01), after
hich blood pressures stabilized. Ambulatory blood pres-
ures were constant over time in sham-treated mice. Elastic
odulus of the aorta was similar between treatment groups,
hereas arterial elastance was significantly greater in G6-
1–treated mice (Table 2), indicating a marked increase in
fterload without any major alterations in the mechanical
roperties of the aorta. On aortic histology, medial thick-
ess and indices of elastin content were not different in
6-31–treated compared with control mice (Fig. 1). There
as a nonsignificant trend toward more elastin fragmenta-
ion in G6-31–treated mice, although the degree of frag-
entation was mild or less in all animals. Post-treatment
lasma angiotensin II concentration was higher in G6-31–
reated compared with control mice (47  17 pg/ml vs. 78 
6 pg/ml, p  0.01, n  12 each), whereas myocardial
elastin layer thickness for control and G6-31–treated mice after 5 weeks of ther-
p  NS by Mann-Whitney and chi-square analysis. (E) Elastin staining of the
elastic laminae. Scale bar  20 m. Four measurements were made for 8 miced (C)
score.
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different between groups (0.20  0.01 vs. 0.23  0.03, p 
0.12; n  5 each).
MBV and MBF. Functional MBV in the LV myocardium
at baseline and after therapy were similar between treatment
groups (Fig. 2). For all groups, there was a nonsignificant
trend for an age-related decrease in myocardial MBV.
Figure 2 Mean (SEM) MBV in the
Myocardium and Skeletal Muscle
Volumes were measured at baseline (Wk 0) and after 5 weeks of therapy
(Wk 5). Microvascular blood volume (MBV) for skeletal muscle represents val-
ues calculated for the capillary compartment.
Figure 3 Skeletal Muscle MBF
(A) Mean (SEM) microvascular blood flow (MBF) at rest. (B) Mean (SEM) M
contrast-enhanced ultrasound images from the proximal hindlimb obtained after th
and during contractile exercise. BG  background image.Functional MBV in skeletal muscle at baseline and after
therapy was similar between the treatment groups and did
not change with age (Fig. 2). Skeletal muscle MBF at
baseline and after 5 weeks of therapy was also similar
between the treatment groups (Fig. 3A), as was hyperemic
MBF during contractile exercise measured at 5 weeks
(Fig. 3B). Skeletal muscle microvascular density on immu-
nohistochemistry was similar for control and G6-31–treated
mice (1.3  0.9 vs. 1.2  0.6 103 fractional area;
examples shown in Online Fig. C).
Renal perfusion and histology. Renal vascular resistance
measured after completion of treatment was significantly
increased in G6-31–treated compared with control animals
(37 12 vs. 27 13 mm Hg·min·g/ml, p 0.05), and was
significantly reduced in G6-31–treated mice when also
treated with ramipril (15  10 mm Hg·min·g/ml). Treat-
ent with G6-31 increased both urinary albumin excretion
nd serum creatinine (Fig. 4). On histology, cortical glo-
erular pathology was present in the majority of animals
reated with G6-31, which ranged from a focal increase in
esangial matrix to severe diffuse glomerulosclerosis associated
ith dense fibrin deposition (Figs. 4C and 5, Online Fig. D).
hese changes were isolated to nephrons in the outer cortex.
here was a nonsignificant trend toward less glomerular
athology in the G6-31ramipril group (Fig. 4C). There was
o evidence for tubulointerstitial disease.
ring contractile exercise measured after 5 weeks of therapy. (C) Examples of
-power destructive pulse sequence and corresponding time-intensity data at restBF du
e high
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Angiogenesis and remodeling of the existing vascular circuit
play a critical role in solid tumor growth, invasion, and
metastasis. Antiangiogenic agents have been developed as
treatments for cancer therapy. The VEGF-A family of
growth factors have been therapeutically targeted by either
direct antibody-based inhibition of VEGF or small mole-
cule, broad-spectrum inhibitors of receptor tyrosine kinases
that include VEGF receptors. The most frequent side effect
of these therapies is clinically significant and sometimes
persistent hypertension (2–4). The aim of this study was to
employ advanced noninvasive cardiovascular and microvas-
cular imaging methods to characterize potential mecha-
nisms responsible for hypertension and the cardiovascular
adaptations that follow.
We studied animals after 5 weeks of therapy with an
anti-VEGF-A antibody given at a dose 2-fold higher than
maximally effective doses for inhibiting tumor xenograft
growth in mice (20). Therapy with G6-31 resulted in
systemic hypertension in anesthetized and in conscious
ambulatory mice. Aortic histology and elastic modulus
suggested that alterations in the mechanical properties of
the great vessels did not play a major role. Arterial elastance,
reflecting the arterial pressure–SV relation, was substantially
higher in G6-31–treated mice, indicating an increased
afterload state (17), which was associated with an increase in
LV mass, concentric hypertrophy, and a decline in both SV
and VcF. Integration of echocardiographic and hemody-
namic data indicated that the decline in SV and VcF were
probably due to increased afterload rather than a decrease of
LV systolic function or contractility. In other words, the
increase in afterload with VEGF inhibition led to greater
Figure 4 Renal Function and Histology
(A) Mean (SEM) urinary albumin excretion at weeks 2 to 5 of therapy. (B) Serum
thology scores for glomerular disease; p  0.001 by Kruskal-Wallis test for treatm
for all treatment groups.end-systolic wall stress that produces a predictable decreasein VcF according to the force–velocity relation (21). The
similar post-treatment values for LV dp/dt and for the end-
systolic pressure to LV dimension relation, a surrogate for
end-systolic elastance, between groups argues against any
reduction in LV contractility or systolic function.
One of the primary aims of our study was to examine
whether reduced functional capillary density plays a role in
the systemic hypertension during anti-VEGF therapy. The
use of CEU in the current study adds important new
information on functional capillary density in tissues other
than the skin. In many major vascular beds, only a fraction
of capillaries are actively perfused under resting conditions
(15,16,22). CEU can quantify MBV and has been used to
evaluate the adequacy of microvascular recruitment in re-
sponse to physiological states such as exercise and physio-
logical hyperinsulinemia that require an increase in muscle
or myocardial capillary surface area for nutrient delivery
(15,16). This was the first study to our knowledge to
examine reduced functional capillary density as a cause of
hypertension from VEGF inhibitors. We failed to find any
reduction in functional myocardial or skeletal muscle capil-
lary density. The age-related decrease in myocardial MBV
likely reflected parallel age-related trends in LV function,
and hence oxygen demand.
Our CEU measurements of MBV and myocardial phos-
phorylated eNOS do not necessarily exclude a role of
reduced NO availability in VEGF-inhibitor hypertension.
NO-mediated vasodilation, including through VEGF sig-
naling, may still be important in regulation of peripheral
arterial tone (11). However, our studies are complementary
to prior studies in that they exclude significant functional
microvascular rarefaction but also implicate increased
tinine at the end of 5 weeks of therapy. p  0.05 versus controls. (C) Histopa-
lated differences. *p  0.05 versus controls for intergroup comparisons; n  6crea
ent-replasma angiotensin II in the development of hypertension
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Cardiovascular Effects of Anti-VEGF Therapy for Cancer August 14, 2012:618–25and ventricular remodeling during VEGF inhibition. The
angiotensin-converting enzyme inhibitor ramipril had a
salutary effect on almost all cardiovascular and hemody-
namic derangements in G6-31–treated mice, although this
does not necessarily imply that angiotensin II was the only
mediator of hypertension.
With regard to the renal changes, the interaction of
angiotensin and NO in regulating afferent and efferent
arteriolar tone, renal blood flow, and glomerular filtration
rate has been well characterized (23). It is feasible that
A
C
E
G
Figure 5 Examples of Histopathology From the Outer Renal Co
(A, C, E, and G) Control mice and (B, D, F, and H) G6-31–treated mice. Examples
(E and F), and fibrin staining (G and H representing sections that were directly ad
glomeruli that were graded as normal (A and C) and severe mesangial change (B
ble by CD31 staining (E). Examples of PAS staining for G6-31 mice and fibrin/CD3altered renal afferent–efferent arteriolar resistance balancefrom high plasma angiotensin II, possibly in combination
with low NO production, may have had a role in the
development of proteinuria and the increase in renal vascu-
lar resistance in G6-31–treated mice. Inhibition of VEGF
has also been associated with glomerular endothelial alter-
ations and a thrombotic microangiopathy (13,14). We
observed outer cortical glomerular mesangial proliferation
after G6-31 and diffuse fibrin deposition, which has been
previously described with VEGF inhibition (14,24). There
was no evidence for advanced thrombotic microangiopathy
rom Control and G6-31–Treated Mice
e periodic acid–Schiff (PAS) staining (A to D), endothelial staining with CD31
to corresponding CD31 staining sections). The PAS staining examples show
). Arrows (G) illustrate the location of nonstaining glomeruli that are clearly visi-
rlay images with confocal microscopy are provided in the Online Appendix.B
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inhibition. Whether the glomerular structural and functional
abnormalities were due to altered afferent/efferent vasoregula-
tory balance, direct glomerular effects of VEGF, or simply to
the hypertension is not clear. However, we did observe that
treatment with ramipril had a salutary effect on renal patho-
logic changes and especially on renal vascular resistance.
Study limitations. First, we did not evaluate the effect of
ither dose or duration of anti-VEGF therapy. We believe
he 5-week time interval is appropriate to study the deter-
inants of hypertension, given the temporal course of hyper-
ension in humans. However, it has been shown that angio-
enesis is important in the response to pressure overload (25),
so that longer studies may have revealed progression to systolic
functional decline associated with a decrease in functional
myocardial MBV. The dose of G6-31 was based on previous
studies evaluating efficacy of neovascularization in murine
tumor models (20). The lack of increased myocardial collagen
in the G6-31–treated animals was an unexpected finding if we
believe that angiotensin II may have played a role in LV
remodeling during VEGF inhibition. It is possible that this
finding reflects the short treatment duration.
The most important limitation of this study is that we
have not provided evidence for any 1 mechanism for
hypertension during anti-VEGF therapy. We believe that
the process is likely complex and multifactorial. However,
we have shown that antibody-mediated VEGF inhibition
produces rapid-onset hypertension, increased afterload, and
LV remodeling with reduced SV, but without impairment
in LV systolic function or contractility. We have also
excluded the pathophysiological contributions from func-
tional capillary loss in large microvascular beds or abnormal
arterial elastic properties. We have also detected an increase
in plasma angiotensin II and that angiotensin-converting
enzyme inhibitors appear to be an effective preventive
strategy against, not only the hypertension, but also the
adverse cardiac effects of VEGF inhibition.
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For an expanded Methods section and supplementary figures,
please see the online version of this paper.
